Pacira BioSciences, Inc. (PCRX): Total Liabilities
$571.81M
As of 2025-12-31
$572.00M
As of 2026-06-30
-14.2%
3-year compound annual growth
-2.7%
5-year compound annual growth
+12.9%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $571.81M | -26.2% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $775.17M | +10.1% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $704.26M | -22.3% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $906.19M | -32.6% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $1.34B | +105.4% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $654.83M | +37.5% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $476.12M | +29.3% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $368.13M | +5.5% | 2020-02-21, Balance as of period end |
| 2017-12-31 | $348.89M | +102.3% | 2019-02-28, Balance as of period end |
| 2016-12-31 | $172.49M | +1.9% | 2018-02-28, Balance as of period end |
| 2015-12-31 | $169.34M | n/c | 2017-03-01, Balance as of period end |
| 2014-12-31 | $154.93M | +20.5% | 2016-02-25, Balance as of period end |
| 2013-12-31 | $128.57M | +178.3% | 2015-02-24, Balance as of period end |
| 2012-12-31 | $46.20M | -29.2% | 2014-02-25, Balance as of period end |
| 2011-12-31 | $65.22M | -43.3% | 2013-03-07, Balance as of period end |
| 2010-12-31 | $114.94M | n/a | 2012-03-27, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $571.81M | -26.2% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $840.49M | -0.6% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $390.93M | +17.6% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $796.00M | -12.2% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $188.85M | +17.3% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $196.03M | +37.9% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $1.36B | -5.5% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $1.60B | +29.3% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $601.51M | +17.6% |
Compare PCRX, AMPH, SUPN, EBS side by side · Screen every company in Pharmaceutical Preparations ↗